CA2355650A1 - Methods and compositions for decreasing allergic reactions to surface allergens - Google Patents
Methods and compositions for decreasing allergic reactions to surface allergens Download PDFInfo
- Publication number
- CA2355650A1 CA2355650A1 CA002355650A CA2355650A CA2355650A1 CA 2355650 A1 CA2355650 A1 CA 2355650A1 CA 002355650 A CA002355650 A CA 002355650A CA 2355650 A CA2355650 A CA 2355650A CA 2355650 A1 CA2355650 A1 CA 2355650A1
- Authority
- CA
- Canada
- Prior art keywords
- allergen
- ige
- bind
- masking
- epitopes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 69
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 24
- 230000003247 decreasing effect Effects 0.000 title claims description 6
- 238000009739 binding Methods 0.000 claims abstract description 53
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 35
- 230000000873 masking effect Effects 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 208000026935 allergic disease Diseases 0.000 claims abstract description 21
- 229920000126 latex Polymers 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 10
- 230000002009 allergenic effect Effects 0.000 claims abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 48
- 239000000463 material Substances 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 14
- 239000004816 latex Substances 0.000 claims description 10
- 210000003630 histaminocyte Anatomy 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 210000003491 skin Anatomy 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 208000030961 allergic reaction Diseases 0.000 claims description 4
- 210000004209 hair Anatomy 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 2
- 102000009438 IgE Receptors Human genes 0.000 claims 2
- 108010073816 IgE Receptors Proteins 0.000 claims 2
- 239000002085 irritant Substances 0.000 claims 2
- 231100000021 irritant Toxicity 0.000 claims 2
- 108010060231 Insect Proteins Proteins 0.000 claims 1
- 101000952180 Morus alba Mulatexin Proteins 0.000 claims 1
- 210000003746 feather Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract description 27
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract description 27
- 239000000427 antigen Substances 0.000 abstract description 24
- 108091007433 antigens Proteins 0.000 abstract description 24
- 102000036639 antigens Human genes 0.000 abstract description 24
- 230000007815 allergy Effects 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 9
- 108020004635 Complementary DNA Proteins 0.000 abstract description 8
- 230000000172 allergic effect Effects 0.000 abstract description 6
- 208000010668 atopic eczema Diseases 0.000 abstract description 6
- 241000282326 Felis catus Species 0.000 abstract description 5
- 230000003278 mimic effect Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 23
- 229960004784 allergens Drugs 0.000 description 20
- 239000000126 substance Substances 0.000 description 13
- 230000000903 blocking effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000010561 standard procedure Methods 0.000 description 10
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000238876 Acari Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002981 blocking agent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 244000043261 Hevea brasiliensis Species 0.000 description 3
- 101800002189 Hevein Proteins 0.000 description 3
- 101710194991 Pro-hevein Proteins 0.000 description 3
- 241000258242 Siphonaptera Species 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001674044 Blattodea Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- WKMZPSWMEXVKKG-XITFREQTSA-N hevein Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CS)C(=O)NCC(=O)OC(=O)CC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CNC2=CC=CC=C12 WKMZPSWMEXVKKG-XITFREQTSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108700021041 Disintegrin Proteins 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 108010030511 potato lectin Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- -1 scents Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21611798A | 1998-12-18 | 1998-12-18 | |
| US09/216,117 | 1998-12-18 | ||
| PCT/US1999/030238 WO2000035484A2 (en) | 1998-12-18 | 1999-12-17 | Methods and compositions for decreasing allergic reactions to surface allergens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2355650A1 true CA2355650A1 (en) | 2000-06-22 |
Family
ID=22805772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002355650A Abandoned CA2355650A1 (en) | 1998-12-18 | 1999-12-17 | Methods and compositions for decreasing allergic reactions to surface allergens |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20010051155A1 (enExample) |
| EP (1) | EP1140169A2 (enExample) |
| JP (1) | JP2004538237A (enExample) |
| AU (1) | AU2196500A (enExample) |
| CA (1) | CA2355650A1 (enExample) |
| WO (1) | WO2000035484A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020019009A1 (en) * | 1999-12-09 | 2002-02-14 | Roggen Erwin Ludo | High throughput screening (HTS) assays |
| US7060687B2 (en) | 2001-02-07 | 2006-06-13 | Genmont Biotechnology Co. | Live vaccines for allergy treatment |
| US20020197268A1 (en) * | 2001-06-08 | 2002-12-26 | Hsu Ching-Hsaing | Allergen-containing milk for allergy treatment |
| JP3642340B2 (ja) * | 2003-03-28 | 2005-04-27 | ダイキン工業株式会社 | 有害物質除去方法、並びに、それに用いる空気浄化用フィルタ、拭き取りシートなどの有害物質除去材、及び、その保管方法 |
| CA2693416C (en) * | 2007-07-09 | 2018-01-09 | Nestec S.A. | Methods for reducing allergies caused by environmental allergens |
| US9388236B2 (en) | 2007-07-09 | 2016-07-12 | Nestec Sa | Methods for reducing allergies caused by environmental allergens |
| EP2022507A1 (en) * | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| US8962241B2 (en) * | 2010-07-20 | 2015-02-24 | California Institute Of Technology | Triggered molecular geometry based bioimaging probes |
| US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
| EP3760223A1 (en) | 2013-04-03 | 2021-01-06 | N-Fold Llc | Nanoparticle composition for desensitizing a subject to peanut allergens |
| EP3631464A1 (en) * | 2017-05-25 | 2020-04-08 | Société des Produits Nestlé S.A. | Methods for enabling pet ownership |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512283A (en) * | 1990-07-06 | 1996-04-30 | Allergene, Inc. | Methods for the selective suppression of an immune response to dust mite der Pi |
| JPH08501799A (ja) * | 1992-12-21 | 1996-02-27 | タノックス バイオシステムズ インコーポレイテッド | アレルゲン特異的ＩｇＡモノクローナル抗体及びアレルギー治療のための関連物質 |
| WO1995012420A1 (en) * | 1993-11-04 | 1995-05-11 | Bsi Corporation | Barrier coatings for surfaces |
-
1999
- 1999-12-17 JP JP2000587803A patent/JP2004538237A/ja not_active Withdrawn
- 1999-12-17 WO PCT/US1999/030238 patent/WO2000035484A2/en not_active Ceased
- 1999-12-17 EP EP99966427A patent/EP1140169A2/en not_active Withdrawn
- 1999-12-17 AU AU21965/00A patent/AU2196500A/en not_active Abandoned
- 1999-12-17 CA CA002355650A patent/CA2355650A1/en not_active Abandoned
-
2001
- 2001-07-02 US US09/897,864 patent/US20010051155A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2196500A (en) | 2000-07-03 |
| WO2000035484A3 (en) | 2000-10-19 |
| EP1140169A2 (en) | 2001-10-10 |
| US20010051155A1 (en) | 2001-12-13 |
| WO2000035484A2 (en) | 2000-06-22 |
| JP2004538237A (ja) | 2004-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2319437C (en) | Methods and reagents for decreasing allergic reactions | |
| DE69931377T2 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
| Chan-Yeung et al. | Aetiological agents in occupational asthma | |
| dos Santos Pinto et al. | Proteomic view of the venom from the fire ant Solenopsis invicta Buren | |
| US5670626A (en) | Allergen-specific human IgA monoclonal antibodies for mucosal administration | |
| TWI471565B (zh) | 鑑定過敏原性蛋白質和肽之方法 | |
| Machiels et al. | Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. | |
| US20010051155A1 (en) | Methods and compositions for decreasing allergic reactions to surface allergens | |
| EP1322330B1 (en) | Modulation of allergic response | |
| Chippaux et al. | Production and use of snake antivenin | |
| JP2004538237A5 (enExample) | ||
| Khurana et al. | Allergenic extracts to diagnose and treat sensitivity to insect venoms and inhaled allergens | |
| JP6073239B2 (ja) | 抗原隠蔽剤としての使用のための、ヒトラクトフェリン誘導ペプチド | |
| WO2005028622A2 (en) | Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions | |
| WO2000052154A2 (en) | Methods and reagents for decreasing clinical reaction to allergy | |
| Arbesman et al. | Allergenic potency of bee antigens measured by RAST inhibition | |
| Özdemir | Cockroach allergy, respiratory allergic diseases and its immunotherapy | |
| JPH06510752A (ja) | アレルギー治療のためのｐ物質の使用方法 | |
| EP0714662A1 (en) | Antiallergic agent | |
| EP0888541B1 (en) | Cryptic peptides and method for their identification | |
| Offerle et al. | The history of allergic disease between 1971 and 2017: How much do changes in human activity explain the rise in three separate forms of food allergy | |
| SHARMA et al. | PRODUCTION OF POLYCLONAL ANTIBODIES AGAINST INDIAN PAPER WASP ROPALIDIA MARGINATA VENOM TOXINS AND THEIR EFFICACY IN THE REVERSAL OF TOXIC EFFECTS | |
| JP2918795B2 (ja) | アレルギー疾患治療のための植物自己不和合性受容体蛋白（ｓｌｇおよびｓｒｋ）組成物 | |
| Chapman et al. | Cockroach allergens, environmental exposure, and asthma | |
| Gepp | Investigation of antibody responses of birch pollen allergic individuals by using chimeric allergens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |